Tirzepatide reduced heart failure events by up to 59% and improved exercise capacity, symptoms, quality of life, and medication burden in obese patients with HFpEF over 2 years.
Up to 59% fewer heart failure eventsTirzepatide reduced the combined risk of cardiovascular death or worsening heart failure by 33–59% compared to placebo over a median of 2 years in obese HFpEF patients.
What the researchers found
In a double-blind randomized trial of 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide (up to 15 mg weekly) produced comprehensive improvements across every clinical measure over a median of 104 weeks.
Compared to placebo, tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure events by 33–59% (hazard ratios 0.41–0.67 depending on analysis). At 52 weeks, tirzepatide improved the Kansas City Cardiomyopathy Questionnaire score by 6.9 points, increased 6-minute walk distance by 18.4 meters, improved quality of life (EQ-5D-5L), improved NYHA functional class, enhanced patient-reported well-being, and reduced heart failure medication burden. The hierarchical composite win ratio was 1.63, meaning tirzepatide patients were 63% more likely to have a better outcome than placebo patients.
Why it matters
Heart failure with preserved ejection fraction is one of the most common and difficult-to-treat forms of heart failure, especially in people with obesity. Until recently, few therapies showed meaningful benefit. This trial demonstrates that tirzepatide doesn't just help patients lose weight — it fundamentally improves their heart failure across multiple dimensions including survival, symptoms, exercise capacity, and quality of life. Published in Circulation, this represents some of the strongest evidence yet for GLP-1 class drugs in cardiovascular disease beyond diabetes.
The numbers in context
n=731 · HR 0.41–0.67 for CV death/worsening HF · +6.9 pts KCCQ score · +18.4 m walk distance · Win ratio 1.63 · Median 104 weeks · BMI 38.2 · Age 65.2 years
How the study worked
Double-blind, placebo-controlled randomized trial (SUMMIT trial). 731 patients with class II–IV heart failure, ejection fraction ≥50%, and BMI ≥30 were randomized to tirzepatide (titrated up to 15 mg subcutaneous weekly) or placebo added to standard heart failure therapy. Median follow-up was 104 weeks. Primary endpoints were the combined risk of cardiovascular death or worsening heart failure, and change in KCCQ Clinical Summary Score. Extended analyses included 6-minute walk distance, quality of life, NYHA class, medication burden, and a hierarchical composite.
Who was studied
731 patients with heart failure (preserved ejection fraction ≥50%), BMI ≥30, class II–IV, mean age 65.2 years, 53.8% female
What this study cannot tell us
The study population was predominantly obese patients with HFpEF, so results may not generalize to heart failure with reduced ejection fraction or non-obese patients. The titrated dose of up to 15 mg is the maximum tirzepatide dose, which may not be tolerable for all patients. Gastrointestinal side effects typical of GLP-1 drugs were not detailed in this analysis.
How to read the evidence
This is a large, double-blind, placebo-controlled randomized trial published in Circulation with a 2-year median follow-up. It meets the highest standards for clinical evidence, with consistent benefits across multiple predefined endpoints.
When this study was published
Published in 2025. This is current, landmark evidence from the SUMMIT trial and represents the state of the art for tirzepatide in heart failure.
The bigger picture
This trial is part of a growing body of evidence that GLP-1 class drugs do far more than help with weight and blood sugar. The SUMMIT trial positions tirzepatide as a potential game-changer for HFpEF, a condition that affects millions and has long frustrated cardiologists. Combined with semaglutide's cardiovascular outcome trials, these results suggest that incretin-based peptides may become foundational therapies in cardiology.
Questions still open
- Are the heart failure benefits primarily driven by weight loss, or does tirzepatide have direct cardiac effects independent of weight?
- Would patients with heart failure and reduced ejection fraction (HFrEF) see similar benefits?
- How do the heart failure outcomes compare between tirzepatide and semaglutide in similar patient populations?
Common questions
Is tirzepatide approved for heart failure?
How much did patients' daily lives actually improve?
Read the original research
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
Circulation, 151(10), 656-668
Citation
Zile, Michael R; Borlaug, Barry A; Kramer, Christopher M; Baum, Seth J; Litwin, Sheldon E; Menon, Venu; Ou, Yang; Weerakkody, Govinda J; Hurt, Karla C; Kanu, Chisom; Murakami, Masahiro; Packer, Milton. (2025). Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.. Circulation, 151(10), 656-668. https://doi.org/10.1161/CIRCULATIONAHA.124.072679